PTC
MRNA icon

Private Trust Company’s Moderna MRNA Stock Holding History

Private Trust Company’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.5K Buy
364
+33
+10% +$1.71K ﹤0.01% 1673
2026
Q1 		$16.8K Buy
331
+51
+18% +$2.38K ﹤0.01% 1777
2025
Q4 		$8.26K Buy
280
+192
+218% +$5.22K ﹤0.01% 2008
2025
Q3 		$2.27K Sell
88
-95
-52% -$2.65K ﹤0.01% 2328
2025
Q2 		$5.05K Sell
183
-544
-75% -$14.3K ﹤0.01% 2063
2025
Q1 		$20.6K Buy
727
+222
+44% +$7.88K ﹤0.01% 1538
2024
Q4 		$21K Buy
505
+226
+81% +$10.8K ﹤0.01% 1474
2024
Q3 		$18.6K Sell
279
-27
-9% -$2.48K ﹤0.01% 1500
2024
Q2 		$36.3K Hold
306
– – ﹤0.01% 1228
2024
Q1 		$32.6K Sell
306
-133
-30% -$13.4K ﹤0.01% 1273
2023
Q4 		$43.7K Sell
439
-227
-34% -$19.1K 0.01% 1113
2023
Q3 		$68.8K Sell
666
-1,088
-62% -$121K 0.01% 915
2023
Q2 		$213K Buy
1,754
+1,236
+239% +$165K 0.03% 539
2023
Q1 		$79.6K Buy
518
+346
+201% +$57.1K 0.01% 852
2022
Q4 		$31K Sell
172
-180
-51% -$29.4K ﹤0.01% 1133
2022
Q3 		$42K Buy
352
+2
+0.6% +$303 0.01% 952
2022
Q2 		$50K Buy
+350
New +$50K 0.01% 921

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Private Trust Company's MRNA Position: Q2 2026 in Review

Private Trust Company increased its Moderna (MRNA) stake by 10% in Q2 2026, buying an estimated $1.71K and bringing the position to 364 shares worth $25.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1673.

Private Trust Company first reported a position in MRNA in Q2 2022 and has held it in 17 quarters since. The position peaked at $213K in Q2 2023. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Private Trust Company held 364 shares of Moderna worth $25.5K as of Q2 2026.
  • Private Trust Company bought 33 Moderna shares in Q2 2026, an estimated $1.71K.
  • Moderna made up ﹤0.01% of Private Trust Company's portfolio in Q2 2026, its #1673 holding.
  • Private Trust Company first reported a position in Moderna in Q2 2022 and has held it in 17 quarters since.
  • Private Trust Company's Moderna position peaked at $213K in Q2 2023.
  • 777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Private Trust Company's 13F filing for Q2 2026, filed 28 Jul 2026.